Panax notoginseng

Panax notoginseng is a traditional Chinese herb containing ginsenosides Rb1 and Rg1 that improve circulation through vasodilation and anti-inflammatory effects. Clinical studies show it enhances stroke recovery outcomes and lung function in COPD patients.

Origin & History

Panax notoginseng is a perennial herb native to southwestern China, primarily sourced from the roots and rhizomes of the plant (family Araliaceae). It is extracted using water decoction or ethanol extraction methods to isolate active triterpenoid saponins (ginsenosides), which are standardized to 85-95% total saponins in preparations like Xuesaitong.

Historical & Cultural Context

In Traditional Chinese Medicine, Panax notoginseng (Sanqi) has been used for centuries to stop bleeding, resolve blood stasis, and treat trauma and cardiovascular issues. It remains one of the most valued herbs in TCM for promoting blood circulation and reducing inflammation.

Health Benefits

• Improves stroke recovery - Large RCT (n=2970) showed 89.3% functional independence vs 82.4% placebo at 3 months (PMID: 37338907)
• Enhances lung function in COPD - Meta-analysis of 20 RCTs found improved FEV1, oxygen levels, and reduced blood viscosity (PMID: 38216446)
• Reduces angina symptoms - Clinical studies demonstrate decreased angina frequency, improved ECG, and reduced nitroglycerin use (PMID: 30166105)
• Improves blood coagulation markers - Studies show normalized fibrinogen and D-dimer without increasing bleeding risk
• Supports post-stroke neurological function - Meta-analyses report improved NIHSS scores and Barthel Index (PMID: 38898926)

How It Works

Panax notoginseng's primary bioactive compounds, ginsenosides Rb1 and Rg1, modulate nitric oxide synthase to promote vasodilation and improve microcirculation. These saponins inhibit platelet aggregation through cyclooxygenase pathways and reduce inflammatory cytokines like TNF-α and IL-6. The herb also activates AMPK signaling pathways to enhance cellular energy metabolism.

Scientific Research

A landmark multicenter RCT with 2,970 ischemic stroke patients demonstrated Xuesaitong's superiority over placebo for functional recovery (PMID: 37338907). Meta-analyses covering 20 RCTs in COPD patients (n=1,831) and multiple stroke studies confirm benefits for cardiovascular and neurological outcomes (PMIDs: 38216446, 38898926, 30166105).

Clinical Summary

A large randomized controlled trial (n=2,970) demonstrated that Panax notoginseng significantly improved stroke recovery, with 89.3% of patients achieving functional independence compared to 82.4% in the placebo group at 3 months. A meta-analysis of 20 RCTs found consistent improvements in lung function for COPD patients, including enhanced FEV1 values and oxygen levels alongside reduced blood viscosity. The evidence base consists primarily of studies conducted in Asian populations with dosages ranging from 3-9 grams daily. While results are promising, more research in diverse populations is needed to confirm universal efficacy.

Nutritional Profile

Panax notoginseng root contains negligible macronutrients in therapeutic doses (typically 1–3g/day as powder or 200–600mg standardized extract). Key bioactive compounds include saponins (3–8% dry weight) dominated by notoginsenoside R1 (~0.3–1.2% DW), ginsenosides Rg1 (~1–3% DW) and Rb1 (~1–2% DW), and dencichine (β-N-oxalyl-L-α,β-diaminopropionic acid, ~0.1–0.5% DW). Minor saponins include Rd, Re, and Rc. Also contains flavonoids (quercetin, kaempferol glycosides at ~0.1–0.3% DW), polysaccharides (~5–8% DW with immunomodulatory activity), and trace minerals including iron (~15–25 mg/100g), calcium (~80–120 mg/100g), and zinc (~2–4 mg/100g). Bioavailability of ginsenosides is limited orally (Rg1 absolute bioavailability ~18–32% in humans); gut microbiota convert Rb1 into more bioavailable compound K, making microbiome status a key variable. Notoginsenoside R1 is relatively unique to this species versus Panax ginseng.

Preparation & Dosage

Clinically studied doses of standardized Panax notoginseng saponins range from 120-600 mg/day orally. The most common protocol is 120 mg twice daily for 3-12 weeks, as used in the major stroke RCT. Injections are also available for post-thrombolysis care. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Panax notoginseng pairs strongly with Danshen (Salvia miltiorrhiza), as their combination (e.g., the commercial preparation Compound Danshen Dripping Pills) produces additive effects on platelet aggregation inhibition and microcirculation — tanshinones and salvianolic acids from Danshen complement notoginsenoside R1's vasodilatory and anti-inflammatory actions on NF-κB and TXA2 pathways. Ginkgo biloba (standardized to 24% flavone glycosides and 6% terpene lactones) synergizes via complementary antiplatelet mechanisms — ginkgolides inhibit PAF (platelet-activating factor) while notoginseng saponins suppress ADP-induced aggregation, providing broader platelet pathway coverage relevant to stroke recovery. Astragalus membranaceus (standardized to ≥0.4% astragalosides) complements notoginseng's COPD benefits through additive immunomodulation and anti-fibrotic effects, with astragaloside IV supporting endothelial nitric oxide synthase (eNOS) activity alongside notoginsenoside R1's demonstrated NO-upregulating properties.

Safety & Interactions

Panax notoginseng may increase bleeding risk and should not be combined with anticoagulant medications like warfarin or heparin. Common side effects include mild gastrointestinal upset, dizziness, and headaches at dosages above 6 grams daily. The herb may interact with diabetes medications by enhancing glucose-lowering effects, requiring blood sugar monitoring. Pregnant and breastfeeding women should avoid use due to insufficient safety data and potential hormonal effects.